IRW

IRW is an orally active tripeptide produced from egg white with angiotensin converting enzyme (ACE) inhibitory properties. IRW can prevent high-fat diet (HFD) -induced Non-alcoholic fatty liver disease (NAFLD) by modulating hepatic lipid metabolism and increasing mitochondrial content. IRW decreases hepatic triglyceride content and lipid droplet size. IRW increases the hepatic mitochondrial complexes and citrate synthase activity, phosphorylation of 5’-AMP-activated protein kinase and microsomal triglyceride transfer protein abundance. IRW increases phosphorylated acetyl CoA carboxylase and mitochondrial complexes, IRW can be used for the research of inflammation[1].

Product Specifications

CAS Number

[159718-10-2]

UNSPSC

12352209

Target

Acetyl-CoA Carboxylase; Angiotensin-converting Enzyme (ACE) ; Mitochondrial Metabolism

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Inflammation/Immunology

Smiles

O=C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O)=O)[C@H]([C@@H](C)CC)N

Molecular Formula

C23H35N7O4

Molecular Weight

473.57

References & Citations

[1]Stepheny C. et al. IRW improves diet-induced non-alcoholic fatty liver disease by reducing steatosis associated with increased capacity for oxidative phosphorylation, Journal of Functional Foods, Volume 112, 2024, 105976, ISSN 1756-4646